The age of 18 is an important criterion in judicial trial, immigrant and competitive sports. Consequentially, the estimation of age 18 is a key issue in forensic practice and research. The extremitas sternalis claviculae, iliac crest, third molar, and the proximal limb of the limb bone were usually used as indictors of age 18. The results of the previous studies demonstrated that those indictors could be beneficial to the estimation of age 18. The X-ray, CT, ultrasound and MRI of different indictors were widely utilized for the estimation of age 18, particularly the thin-layer CT. But due to the non-radiation, MRI will be a trend for forensic age estimation in the future. Whilst in the previous studies, the descriptive analysis was applied for the estimation of age 18, but due to the low statistic efficiency, it is unsuitable for forensic age estimation, and the future studies should pay attention to the high efficiency statistical methods, for instance, the ROC curve or the data mining.

Objective To understand genomic copy number variations (CNVs) and ascertain karyotype for a 46,X0, + der(?) fetus, and investigate possibility and superiority of array-based comparative genomic hybridization (array-CGH ) in clinical cytogenetic diagnosis. Methods G-banded chromosome analysis was carried out. The whole genome of the fetus was scanned and analysed by array-CGH. The results of array-CGH were confirmed by RT-qPCR. Results G-banded chromosome analysis showed that the fetal karyotype was 46,X0, +der(?). Array-CGH revealed the derivative chromosome as Y chromosome without CNVs. A total number of 118 submicroscopic CNVs were identified. Comparable results between array-CGH and RT-qPCR were obtained for 9 novel CNVs. Conclusion Comparing with conventional cytogenetic analysis, array-CGH is of high resolution, high-throughput and high accuracy, which provides a technical platform for accurate detection of submicroscopic chromosomal aberrations.

In order to provide reference for treatment of liver tumors using traditional Chinese medicine, we analyzed the research status of liver tumor treatment with traditional Chinese Medicine based on PubMed. By the bibliography information concurrence mining system (BICOMB 2013), the literature were collected and analyzed from PubMed database from the day of establishment to 31 October 2017. CytoScape3.6.1 software was used to draw the Co-occurrence analysis chart of high-frequency subject headings and the subheadings, and SPSS17 statistical software was used to cluster the high frequency subject headings. 365 literatures were collected in total. The amount of published articles is increasing year by year. The literatures were mainly in English. From the literature indicating the author's country, we found that 70％ of the top 10 countries and regions which published the most papers were from Asia. Among them, Chinese scholars ranked first. The top 5 of the high-frequency subject headings and the subheadings were Humans, Male, Animals, Liver Neoplasms/drug therapy and Carcinoma, and Hepatocellular/drug therapy. The research focused on the following 9 aspects: metabolism of liver cells, neoplasms, liver cancer pathology, pharmacological efficacy of liver cancer, relationship between cell proliferation and apoptosis and efficacy; xenograft model antitumor assays in mice, pharmacology of antitumor Chinese herbal medicine or phytogenic drugs, the effects of dose-response relationship, cellular activity and signal transduction on drug efficacy, therapeutic uses of traditional and phytotherapy and the outcome and mortality of liver tumor. By the bibliometric analysis in the field of traditional medicine for liver tumor, we can understand the research direction and development status of this field, which can be reference for prevention and treatment of liver cancer with TCM.

Abiraterone is commonly used as a targeted drug for the treatment of prostate cancer， which commonly causes adverse drug reactions （ADR）， including abnormal liver function， fatigue， nausea and edema， etc. This study reports a 78-year-old man with a history of hepatitis B and liver cirrhosis after prostate cancer resection who was admitted to the First Affiliated Hospital of Henan University of Chinese Medicine. The patient received abiraterone treatment 1 month before admission and developed gastrointestinal symptoms 3 weeks after the treatment and worsened at 4th week with yellowing of the skin， sclera and urine. Unfortunately， the patient died after 5 weeks of abiraterone treatment （1 week after admission）. Based on test and examination results， the patient was diagnosed with acute-on-chronic liver failure （ACLF）. This paper analyzes the patient’s medical history and the relevant treatment in detail. It is evaluated that ACLF and abiraterone are “probably” related based on Naranjo ADR Probability Scale， suggesting abiraterone may induce severe ADR of liver failure in patients with chronic liver diseases such as cirrhosis. These patients should be monitored dynamically for changes in liver function and treated prophylactically with liver-protective drugs if necessary.